WT1 gene transcript assay for relapse in acute leukemia after transplantation.
The WT1 gene is highly expressed in various types of leukemia, particularly in acute type leukemia. The extent of minimal residual disease (MRD) of leukemia can be evaluated by measuring the WT1 gene expression level using a quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) method. The WT1 transcript assay can be applied to almost all patients with leukemia regardless of the presence or absence of chimeric DNA markers. Furthermore, because of the fact that WT1 expression levels increase significantly at relapse compared with those at the time of diagnosis, and because of the decrease in background levels of WT1 expression in bone marrow following allogeneic SCT, the WT1 transcript assay possesses a high degree of sensitivity following allogeneic SCT. Frequent monitoring of the WT1 gene expression level predicts the risk of relapse following allogeneic SCT, and furthermore, the kinetics of WT1 transcripts predict the efficacy of immunomodulation therapy such as donor leukocyte infusion.
Ogawa
Hiroyasu
H
Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Japan. ogawah@imed2.med.osaka-u.ac.jp
Ikegame
Kazuhiro
K
Kawakami
Manabu
M
Tamaki
Hiroya
H
D000208:Acute Disease; D000818:Animals; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D012008:Recurrence; D014158:Transcription, Genetic / Q000235:genetics*; D014180:Transplantation; D025721:WT1 Proteins / Q000235:genetics* / Q000378:metabolism*
D025721:WT1 Proteins